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There are actually two major forms of diabetes: diabetes insipidus and diabetes mellitus.  
Diabetes insipidus (DI) is a term used to describe the obligatory passage of large volumes of 
extremely dilute urine, usually with a consequent increase in thirst and water intake.  DI has 
many causes.  It may result from a failure of production of antidiuretic hormone (vasopressin) 
by the hypothalamus or a failure of the kidney tubules to respond appropriately to 
vasopressin.  Drugs, infections, hormones, and hypercalcaemia can interfere with the action 
of vasopressin on the kidney tubules.  Typically, the urine of patients with DI does not contain 
sugar and would not taste sweet (if you unwisely chose to taste it!). 
The word 'diabetes' is often used synonymously with diabetes mellitus (DM) or 'sugar 
diabetes'.  Mellitus means sweet and DM gets its name from the fact that the urine of patients 
with this disease would taste sweet, whereas the urine of patients with DI would taste bland 
or insipid.  
Diabetes mellitus is a large and important topic. Therefore, in the remainder of these notes, I 
shall consider selected aspects of diabetes mellitus in which there has been some recent 
progress. 
Aetiology / Pathogenesis 
The pancreas has endocrine and exocrine components.  The endocrine pancreas consists of 
numerous small islands of endocrine tissue (the islets of Langerhans) surrounded by a ‘sea’ 
of exocrine glandular tissue that produces digestive enzyme precursors for secretion into the 
intestines.  The islets of Langerhans contain several different kinds of hormone-secreting 
cells; the ones most relevant to this talk are the beta cells, which secrete insulin. DM is the 
most important disease of the endocrine pancreas in dogs and cats.  It arises from an 
absolute or relative deficiency of insulin secretion by the beta cells of the islets of 
Langerhans. 
In humans, DM is categorised into four main types.  These are type 1, type 2, gestational and 
other.  Type 1 is thought to be the most important category in dogs, affecting at least 50% of 
dogs with DM.[1]  Type 1 DM is essentially an autoimmune disease.  There is immune 
destruction of the beta cells in the islets of Langerhans. Some dogs are genetically 
predisposed to this immune destruction, so certain breeds are overrepresented and affected 
individuals may even have a family history of DM. 
Pancreatitis is another important cause of canine DM in the ‘other’ category, reported to 
cause DM in 28% of cases. Actually, this may be an underestimate since chronic, 
smouldering pancreatitis can be difficult to diagnose. During bouts of pancreatitis, which may 
be clinically unapparent, inflammation originating in the exocrine pancreas destroys the 
embedded islets. It is also possible that pancreatic inflammation predisposes to the 
development of autoimmunity against beta cells. Eventually, enough islets are destroyed to 
cause overt DM.  Obesity predisposes dogs to develop pancreatitis, and so indirectly it may 
predispose some dogs to develop DM. Evidence that obesity directly predisposes dogs to 
develop DM is lacking.  Indeed, there is no convincing evidence that type 2 DM is a 
significant disease entity in dogs.  
Some bitches may suffer from the equivalent of gestational diabetes during pregnancy and 
dioestrus, but this is relatively uncommon.[2]  Progesterone stimulates growth hormone to be 
produced by the canine mammary gland.  Growth hormone induces a high degree of insulin 
resistance.  Numerous endocrine diseases and drugs can interfere with the actions of insulin, 
causing so-called insulin resistance. Glucocorticoid therapy (e.g., with prednisolone), 
progestational drugs, hyperadrenocorticism and acromegaly (growth hormone excess) all 
cause insulin resistance and can predispose to DM.  If a dog has concurrent islet damage, 
for example as a result of pancreatitis or immune destruction of beta cells, then DM is all the 
more likely to develop. 
Type 2 DM, sometimes described as non insulin-dependent diabetes mellitus (NIDDM) is 
thought to be the most important type of DM in cats.  As in people, this form of diabetes is 
associated with obesity and physical inactivity and can sometimes be managed without the 
need for insulin injections. In type 2 DM, there is insulin resistance (i.e., a lack of insulin 
glucose-lowering effectiveness in the target tissues) and an insufficient compensatory 
increase in insulin secretion by the beta cells.   Nevertheless, in type 2 DM it is often the 
case that the islets remain capable of producing some insulin.  The amount of insulin 
produced, and the extent of insulin resistance, vary over time. Sometimes insulin production 
dwindles as the disease progresses, but it may be able to rebound if blood glucose 
concentrations can be brought sufficiently under control.  This helps to explain the fact that 
feline diabetes is often transient, going into “remission” with treatment.  It also helps to 
explain why treatments other than insulin injections (e.g., dietary management, increased 
exercise and oral hypoglycaemic drugs) can sometimes be effective in cats and people with 
type 2 DM.  Type 2 diabetes is not the only type of DM in cats.  As in dogs, pancreatitis can 
cause DM and may be under-diagnosed.  Pancreatitis in cats can be very difficult to 
diagnose.  Pancreatic cancer (adenocarcinoma) is another cause of islet destruction and 
DM.  Pancreatic amyloid accumulation often occurs in cats with DM, but it is unclear whether 
this is a cause or consequence of feline DM, or both.  Cats also suffer (albeit infrequently) 
from acromegaly and hyperadrenocorticism, both of which can cause DM in cats.  
Hyperthyroidism tends to cause more modest insulin resistance. 
To complicate matters, the distinction between IDDM and NIDDM is not hard and fast.  
Prolonged hyperglycaemia of any cause can diminish the ability of the beta cells to produce 
insulin, either temporarily or permanently.  This sometimes reversible effect of prolonged 
hyperglycaemia is called 'glucose toxicity'.  One would usually expect an endocrine tissue to 
hypertrophy when stimulated.  Unusually, when beta cells are stimulated to secrete a large 
amount of insulin over a period of time they may sustain damage and undergo programmed 
cell death.  So an obese cat starting with insulin resistance (NIDDM) and high blood insulin 
levels may eventually become completely dependent upon insulin injections and incapable of 
producing any insulin from its islets. 
An excellent article entitled “Canine and Feline Diabetes Mellitus: Nature or Nurture” by 
Jacquie Rand and her colleagues at the University of Queensland [1] was published in the 
Journal of Nutrition fairly recently and is well worth a read. 
Epizootiology 
The incidence of feline diabetes mellitus has been estimated at 0.25-2%.  In the UK, the 
incidence of canine DM has been estimated at 0.32%.  There is some evidence that these 
incidence rates may be increasing. For the cats, this may in part be because more of them 
are obese and doing less exercise.  
In both dogs and cats, DM tends to be diagnosed in middle-aged to older animals.  
Infrequently, DM is diagnosed in young animals less than a year of age.  Neutering and 
being male are other risk factors for feline DM.  Conversely, bitches are affected twice as 
often as male dogs. 
Burmese cats are reported to be much more prone to develop DM than are other breeds in 
Australia, New Zealand and the UK.  The same may hold true in other parts of the world.  In 
some parts of the world, 1 in 50 Burmese cats reportedly has DM and a staggering 1 in 10 
Burmese cats over 8 years of age has the disease!  Cavalier King Charles Spaniels, 
Samoyeds, Schnauzers, Australian terriers, miniature poodles, Rottweilers and Bichon frise 
are among the canine breeds reported to have a high risk of developing DM, whereas 
German shepherds, collies, Golden retrievers and Labrador retrievers are at much lower risk 
than other breeds. 
Interestingly, canine DM is diagnosed more frequently in the winter months than in the 
summer.  Whether this reflects closer observation of dogs by owners during the winter, 
different behaviour of dogs during colder weather, or a genuine seasonal variation in the 
onset or progression of pancreatic pathology is uncertain. 
Diagnosis 
Diagnosis is based on signalment, history (polyuria, polydipsia, polyphagia, weight loss), 
physical examination findings and the presence of persistent fasting hyperglycaemia with 
glucosuria. The presence of ketonuria confirms diabetic ketosis or ketoacidosis. Usually, no 
attempt is made to distinguish IDDM from NIDDM at initial presentation.  That distinction may 
only become apparent weeks or months later. 
A thorough diagnostic investigation is important in diabetic patients because often there are 
other, concurrent illnesses that may affect the response of the patient to management of its 
DM.  For example, urinary tract infections are common in patients with DM and may cause 
stress, inducing a degree of insulin resistance and affecting (i.e., diminishing) the 
responsiveness of the patient to insulin therapy.  A thorough diagnostic investigation may 
also reveal an underlying cause for insulin resistance, such as hyperadrenocorticism. 
In non-neutered bitches, the possibility of gestational or dioestrus DM should be considered.  
A pragmatic approach is to offer to neuter intact bitches and see whether the DM resolves. 
Monitoring 
There are some fairly new tools for monitoring diabetic dogs and cats, but the mainstays 
remain the history and physical examination (including body weight and condition score).  
Assessment by the owner of the animal's water intake is particularly important.  The owner 
should also be questioned about the animal’s overall health and energy levels.  Because cats 
are so prone to stress hyperglycaemia, micromanagement is to be discouraged and in-
hospital serial blood glucose curves reserved for initial stabilisation and, later on, for 
situations where there is a perceived need to adjust insulin therapy. 
At-home daily urine glucose measurement is unnecessary in many well-managed diabetic 
patients. Occasional monitoring is useful in the following situations: a).  to detect ketonuria or 
persistent absence of glucosuria (possibly indicating insulin overdose);  b). in cats that are in 
DM "remission", to check for recurrence of glucosuria; and c). in cats receiving oral 
hypoglycaemic drugs, to check whether the degree of glucosuria has improved or worsened. 
The adjustment of insulin dose based on morning urine glucose concentration is to be 
discouraged.  Records of morning urine glucose concentrations can help to inform decisions 
about insulin dose adjustments, but daily changes based on morning urine glucose 
concentrations more often lead to difficulties. 
Urine can be collected from litter trays if the normal litter is temporarily replaced with 
aquarium gravel.  Alternatively, there are commercially available urine glucose paper test 
squares that can be mixed with litter (GlucoTest™ Feline Urinary Glucose Detection System; 
Ralston Purina). 
Fructosamines are proteins to which glucose has been irreversibly and non-enzymatically 
bound.  Serum fructosamine concentration gives an indication of the mean blood glucose 
concentration over the last several (1-3) weeks.  Stress hyperglycaemia, which is very short 
lived, does not affect serum fructosamine, but fructosamine may be abnormally low in 
hypoproteinaemic cats and hypoalbuminaemic, hyperlipidaemic and azotaemic dogs.  Serum 
for fructosamine measurement should be separated, frozen and submitted to the laboratory 
on cold packs.  It can be used for diagnosis of DM and for monitoring patients under 
treatment for DM.  Unfortunately, some dogs and cats whose diabetes seems to be very well 
controlled have abnormally high or low serum fructosamine concentrations. 
At-home serial blood glucose curves can be generated by owners who are dextrous and 
willing to prick the marginal ear veins (or paw pads) of their cat.  Such owners are usually 
motivated enough to buy their own portable glucometer.  An excellent Web-based resource 
is available, so that owners can decide whether or not they are willing to attempt this 
procedure (http://www.sugarcats.net/sites/harry).  It should be borne in mind that many 
portable glucometers generate results that are different (often lower) than reliable reference 
methods.  In general, the further the blood glucose is from normal, the less reliable is the 
result. 
Recently, a continuous glucose monitoring system has been assessed for use in diabetic 
dogs.[3]  Such systems allow for continuous, minimally invasive glucose monitoring.  A 
glucose sensor is implanted subcutaneously using a 22-gauge needle attached to a spring-
loaded device.  The sensor can remain in place for up to 72 hours.  Interstitial fluid glucose 
concentrations are measured every few seconds and an average value is reported every five 
minutes.  The sensor and monitor work very much along the lines of a Holter ECG monitor, 
very portable.  Unfortunately, several blood samples need to be taken during each 24-hour 
period, so that the subcutaneous glucose sensor can be properly calibrated.  The device may 
not measure low blood glucose concentrations as reliably as it measures normal and high 
ones. Nevertheless, this new technology holds great promise for monitoring diabetic animals 
at home and in the hospital.  Unfortunately, it is for the moment very expensive. 
Treatment 
Oral hypoglycaemic drugs (e.g., glipizide, glimiperide) are best reserved for cats whose 
owners would choose euthanasia rather than administering insulin injections.  A few weeks 
of extra time may allow owners to come to terms with their cat's diabetes and change their 
minds about learning how to carry out the insulin injections. 
Insulin glargine (Lantus®) is a relatively new human synthetic insulin analogue produced in 
E. coli bacteria using recombinant DNA technology.[4]  The amino acid sequence differs from 
ordinary human insulin at three positions.  Glargine is a clear and colourless solution, not a 
suspension like other long-acting insulins.  It contains 100U/ml insulin and should not be 
diluted before injection.  This is because it is specially formulated to be at pH 4, and dilution 
with most commonly available diluents would change that.  When pH 4 glargine is injected, 
and encounters pH neutral subcutaneous tissues, microprecipitates form immediately.  From 
these, insulin is released gradually over a long period. This is the basis of its long-lasting 
"peakless” effect when used in diabetic people.  Recent work using glargine in cats has 
provided very promising results.  Glargine has a long-lasting effect in cats.  Nevertheless, it 
seems to work best when it is administered twice daily.  Although it is quite expensive, it 
seems to be able to send many cats into “remission”.  When this happens, the overall cost is 
less for the owners than when using more conventional insulins. 
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